MULTIPLE MYELOMA

The BOSTON study delivered promising findings among patients with multiple myeloma treated with selinexor, bortezomib, and dexamethasone vs bortezomib and dexamethasone.

Brea C. Lipe, MD highlights key takeaways and patient outcomes from the PERSEUS phase three trial.

Brea C. Lipe, MD explains the trial design and patient population of PERSEUS phase three trial.

Brea C. Lipe, MD describes the unique treatment technology explored in the PERSEUS phase three trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the GRIFFIN and MASTER trials in patients with newly diagnosed multiple myeloma, as well as the phase 3 Perseus trial. This is the second of 2 articles based on this event.

In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.

Susan Bal, MD, discusses novel targets for relapsed/refractory multiple myeloma at the 2023 Annual Meeting.

Explanation of how these data apply to community oncologists.

Presenting real-world data on the efficacy and safety of teclistamab for R/R MM.

Discussion of the real-world effectiveness of teclistamab in R/R MM and the impact on treatment guidelines and practice.

Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.

A description and overview of teclistamab and its mechanism of action.

Expert insights into the evolving therapeutic landscape for newly diagnosed multiple myeloma, highlighting transplant eligibility, combination regimens, and emerging data.

In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.

Brea C. Lipe, MD, discusses the evolving landscape of multiple myeloma treatment, highlighting the current abundance of drugs and the challenges associated with optimizing their use.

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.

Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.

Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.

Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.

Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.

Douglas W. Sborov, MD, MS, provides a summary of the key details of the 54-year-old patient's medical history and multiple myeloma diagnosis.

Paula Rodriguez-Otero, MD, PhD, discusses the promising results from the phase 3 PERSEUS trial in patients with newly diagnosed, transplant-eligible multiple myeloma.

The approval of talquetamab, a GPRC5D-targeted bispecific T-cell engager, led to discussions in 2 separate Case-Based Roundtable events on therapy sequencing selection, toxicity, and outpatient treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the IFM2009, DETERMINATION, and FORTE trials in patients with newly diagnosed multiple myeloma. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Clinical Case Forum event in partnership with the Empire State Hematology & Oncology Society, Joshua Richter, MD, discussed the GRIFFIN trial and issues in treating newly diagnosed multiple myeloma including minimal residual disease, consolidation, maintenance, and transplant.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, and participants discussed their impressions of the efficacy and safety of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

The treatment combination of isatuximab with carfilzomib, lenalidomide, and dexamethasone resulted in a 100% objective response rate among patients with newly diagnosed multiple myeloma.

Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma—even in those with high-risk features.

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant and D-VRd consolidation and daratumumab/lenalidomide maintenance significantly prolonged progression-free survival.